Challenges and Strategies in an Evolving Chronic Lymphocytic Leukemia (CLL) Treatment Paradigm:
What Does Managed Care Need to Know

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from April 30, 2018 to April 30, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AbbVie and Pharmacyclics

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow and is the most common type of leukemia in adults. Patients with CLL are often diagnosed when they are asymptomatic; therefore, knowing when to initiate treatment may pose a challenge to clinicians. Furthermore, patients with CLL have impaired immune systems and multiple comorbidities, which can complicate management and impact treatment decisions. Fortunately for patients with CLL, several new treatments, including targeted therapies, have recently become available, giving clinicians many new options to improve patient outcomes.

Upon Completion of this activity, participants will be able to:

  • Describe the role of diagnostic testing, staging, biomarkers and prognostic assessment tools in CLL pathway development and their use for informing treatment decisions

  • Examine clinical data on newer therapies for patients with CLL who have received at least one prior therapy

  • Integrate current and new safety and efficacy data evaluating recently approved agents for CLL into clinical pathways taking into consideration cytogenetic abnormalities, patient age, performance status, and comorbidities

  • Apply methods to enable optimal cost management of newer therapies to be realized by multiple CLL stakeholders including managed care organizations

  • Analyze the role of BCL-2 inhibitors in the management of patients with CLL

Faculty: Michael Keating, MB, BS
Clinical Professor
Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center


Dr. Keating serves as a consultant to Celgene and Hoffman LaRoche. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
AbbVie and Pharmacyclics

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue